Open Nav

Please submit your session questions in advance at

Adelene Perkins


Infinity Pharamaceuticals

Adelene Perkins has served as Infinity’s CEO and Chair since 2012, CEO and Board Member since 2009, President from 2008-2009 and EVP and CBO from 2002-2008. Previously, Ms. Perkins served as TransForm Pharmaceuticals’ VP of BD and helped build the company prior to its acquisition by J&J. From 1992-1999 she was at Genetics Institute (GI), now a unit of Pfizer, as VP of emerging businesses and formed and served as CEO of MetaMorphix, a joint venture between GI and Johns Hopkins University. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm. Ms. Perkins received her MBA from Harvard Business School and her BS in chemical engineering from Villanova University. In addition to chairing the Infinity (NASDAQ: INFI) Board, she is on the Boards of Bruker Corporation (NASDAQ: BRKR), Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and is vice chairman of the Board of Project Hope.

This speaker's sessions: